Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: The prospective ANRS EP24 GYNODYN study

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 843-852

  Launay, Odile ^a,b   Tod, Michel ^b   Tschöpe, Inga ^c   Si Mohamed, Ali ^d   Bélarbi, Linda ^b   Charpentier, Charlotte ^d   Goujard, Cécile ^e   Taburet, Anne Marie ^e   Lortholary, Olivier ^a,f   Leroy, Valériane ^c   Bélec, Laurent ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Pôle de Médecine ^*  (France)

^c INSERM   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e BICÊTRE HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONDOM; CONTRACEPTION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; FEMALE GENITAL SYSTEM; GENOTYPE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LOW DRUG DOSE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; VAGINA SECRETION; VAGINAL LAVAGE; VIRUS DETECTION; VIRUS LOAD; VIRUS SHEDDING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PROVIRUSES; RNA, VIRAL; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 80052931819     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1856     Document Type: Article

References (51)

1. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17:455-480. (Pubitemid 36293099)
2. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601. (Pubitemid 33101909)
3. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003; 100:12972-12977. (Pubitemid 37340010)
4. Kelley CF, Sullivan ST, Lennox JL, Evans-Strickfaden T, Hart CE. Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviralexperienced women. AIDS 2010; 24:1361-1366.
5. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-882. (Pubitemid 29159332)
6. Cu Uvin S, Caliendo AM, Reinert SE, et al. HIV-1 in the female genital tract and the effect of antiretroviral therapy. AIDS 1998; 12:826-827. (Pubitemid 28190713)
7. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421. (Pubitemid 30182438)
8. Si-Mohamed A, Kazatchkine MD, Heard I, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000; 182:112-122. (Pubitemid 30497795)
9. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719-725. (Pubitemid 351321556)
10. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17:2169-2176. (Pubitemid 37338890)
11. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42:584-587. (Pubitemid 44162427)
12. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38-42. (Pubitemid 46052218)
13. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-507.
14. Kemal KS, Burger H, Mayers D, et al. HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007; 195:535-545. (Pubitemid 46214396)
15. Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517-2525.
16. Nagot N, Ouedraogo A, Weiss HA, et al. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect 2008; 84:167-170. (Pubitemid 351871485)
17. Cu-Uvin S, Delong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-2497.
18. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101. (Pubitemid 41233212)
19. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
20. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153. (Pubitemid 32378686)
21. Vernazza PL. The debate continues: does 'undetectable' mean 'uninfectious'? HIV Ther 2009; 3:113-116.
22. Vernazza P, Hirschel B, Bernasconi E, Flepp M. [HIVinfected individuals without additional STD and on effective antiretroviral therapy are not sexually infectious]. Schweizerische Ärztezeitung 2008; 89:165-169. German.
23. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004; 292:251-265.
24. Launay O, Tod M, Louchahi K, et al. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother 2004; 48:632-634. (Pubitemid 38141731)
25. Bélec L, Meillet D, Levy M, et al. Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol 1995; 2:57-61.
26. Legoff J, Bouhlal H, Gresenguet G, et al. Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol 2006; 44:423-432. (Pubitemid 43222234)
27. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94:45-54. (Pubitemid 32411477)
28. Bouley M, Briere C, Padoin C, et al. Sensitive and rapid method for the simultaneous quantification of the HIVprotease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 2001; 23:56-60. (Pubitemid 32105966)
29. Jacqmin-Gadda H, Thiebaut R, Chene G, Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 2000; 1:355-368. (Pubitemid 33213542)
30. Beal AD, Ludden T, Boeckmann A. NONMEM users guide. Version VI. Ellicot City, MD: GloboMax, ICON Development Solutions 2006.
31. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21:735-750. (Pubitemid 24052760)
32. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82:17-20. (Pubitemid 46944205)
33. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23:2036-2049.
34. Iversen AK, Larsen AR, Jensen T, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998; 177:1214-1220. (Pubitemid 28194260)
35. Nuovo GJ, Forde A, MacConnell P, et al. In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. Am J Pathol 1993; 143:40-48. (Pubitemid 24058159)
36. Bardeguez AD, Skurnick JH, Perez G, et al. Lymphocyte shedding from genital tract of human immunodeficiency virus-infected women: immunophenotypic and clinical correlates. Am J Obstet Gynecol 1997; 176:158-165. (Pubitemid 127780765)
37. Andréoletti L, Chomont N, Grésenguet G, et al. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis 2003; 188:549-554. (Pubitemid 37011807)
38. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
39. Bruisten SM, Reiss P, Loeliger AE, et al. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1998; 14:1053-1058. (Pubitemid 28371337)
40. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003; 77:12165-12172. (Pubitemid 37339869)
41. Marcelin A-G, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. 16th Conference on Retroviruses and Opportunistic infections (CROI). 8-11 February 2009, Montréal, QC, Canada. Abstract 51.
42. Mbopi-Kéou FX, Grésenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090-1096.
43. Witteck A, Yerly S, Vernazza P. Unusually high HIV infectiousness in an HIV-, HCV- and HSV-2-coinfected heterosexual man. Swiss Med Wkly 2009; 139:207-209.
44. Sha BE, Zariffard MR, Wang QJ, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 2005; 191:25-32. (Pubitemid 40041396)
45. Zara F, Nappi RE, Brerra R, et al. Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sex Transm Infect 2004; 80:108-112. (Pubitemid 38496835)
46. Tuomala RE, O'Driscoll PT, Bremer JW, et al. Cellassociated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviralexperienced women. J Infect Dis 2003; 187:375-384. (Pubitemid 36184578)
47. Sallé B, Brochard P, Bourry O, et al. Infection of macaques after vaginal exposure to cell associated simian immunodeficiency virus. J Infect Dis 2010; 202:337-344.
48. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098-3107. (Pubitemid 26121927)
49. Ellerbrock TV, Lennox JL, Clancy KA, et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001; 184:28-36. (Pubitemid 32568497)
50. Ongradi J, Ceccherini-Nelli L, Pistello M, Specter S, Bendinelli M. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 1990; 6:1433-1436.
51. Cohen J. AIDS research. Treat everyone now? A 'radical' model to stop HIV's spread. Science 2008; 322:1453.